-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Through the performance of commercial companies in the first half of the year, we can see the fundamentals of the industry: the growth rate of industrial and circulation performance has slowed down, and some areas have even experienced negative growth
.
I hope that the industry boom in the second half of the year can be fully boosted!
.
I hope that the industry boom in the second half of the year can be fully boosted!
Recently, the four major listed enterprises in the domestic pharmaceutical business: Sinopharm Holdings, Shanghai Pharmaceutical, China Resources Pharmaceutical and Jointown have successively released their annual reports
for the first half of 2022.
for the first half of 2022.
Overall, the revenue growth rate of the four companies has changed from the double-digit growth of revenue in the same period last year, all of which are single digits, and the growth rate is not much
different from each other.
However, Sinopharm Holdings still maintains its industry leadership, with revenue of 261.
471 billion yuan in the first half of 2022, and its revenue is almost the sum of the revenues of Shanghai Pharmaceutical, China Resources and
Jointown.
different from each other.
However, Sinopharm Holdings still maintains its industry leadership, with revenue of 261.
471 billion yuan in the first half of 2022, and its revenue is almost the sum of the revenues of Shanghai Pharmaceutical, China Resources and
Jointown.
In terms of net profit, China Resources Pharmaceutical performed prominently, with net profit in the first half of 2022 increasing by 26.
2% year-on-year to HK$5.
17 billion, and net profit attributable to the mother significantly increasing by 24.
1% year-on-year to HK$3.
03 billion, becoming the first enterprise in the four companies in terms
of revenue and net profit growth.
2% year-on-year to HK$5.
17 billion, and net profit attributable to the mother significantly increasing by 24.
1% year-on-year to HK$3.
03 billion, becoming the first enterprise in the four companies in terms
of revenue and net profit growth.
The net profit of Jointown continued its negative growth, and the net profit attributable to the mother decreased by 41.
58%
year-on-year.
For the negative growth of profit, Jointown said in the report that the fair value change caused by the change in the fair value of the company's shares held by the company in the same period last year was 1.
193 billion yuan, while the non-recurring profit and loss in the reporting period was only 163 million yuan
.
58%
year-on-year.
For the negative growth of profit, Jointown said in the report that the fair value change caused by the change in the fair value of the company's shares held by the company in the same period last year was 1.
193 billion yuan, while the non-recurring profit and loss in the reporting period was only 163 million yuan
.
For the impact of collection and mining, Jointown said that the benefits outweigh the disadvantages: according to the statistics of 2021, the variety affected by the collection and mining of the company accounts for about 3% of the total business, and this part of the business will have a certain impact due to price reduction, but due to the relatively small proportion, the impact is not large; However, in the long run, the policy will bring rare development opportunities
for the company to expand the pure sales business of the hospital and the out-of-hospital market and the general generation brand promotion business.
for the company to expand the pure sales business of the hospital and the out-of-hospital market and the general generation brand promotion business.
Sinopharm Holdings: Revenue in the first half of 2022 was 261.
471 billion yuan, an increase of 4.
96% year-on-year; Attributable net profit reached RMB3.
694 billion, up 3.
1%
year-on-year.
471 billion yuan, an increase of 4.
96% year-on-year; Attributable net profit reached RMB3.
694 billion, up 3.
1%
year-on-year.
Shanghai Pharmaceutical: Revenue in the first half of 2022 was 111.
707 billion yuan, an increase of 6.
15% year-on-year; Attributable net profit reached 3.
696 billion yuan, an increase of 3.
58%
year-on-year.
707 billion yuan, an increase of 6.
15% year-on-year; Attributable net profit reached 3.
696 billion yuan, an increase of 3.
58%
year-on-year.
CR Pharmaceutical: Revenue in the first half of 2022 was HK$125.
716 billion, an increase of 9.
8% year-on-year; Attributable net profit reached HK$3,025 million, up 24.
1%
year-on-year.
716 billion, an increase of 9.
8% year-on-year; Attributable net profit reached HK$3,025 million, up 24.
1%
year-on-year.
Jointown: Revenue in the first half of 2022 was 67.
984 billion yuan, an increase of 9.
69% year-on-year; Net profit attributable to the mother reached 169 million yuan, down 41.
58%
year-on-year.
984 billion yuan, an increase of 9.
69% year-on-year; Net profit attributable to the mother reached 169 million yuan, down 41.
58%
year-on-year.
In the distribution sector, the four enterprises all showed positive growth, with Jointown showing the largest increase, and the distribution business achieved sales of 59.
197 billion yuan, an increase of 9.
75%
year-on-year.
197 billion yuan, an increase of 9.
75%
year-on-year.
From the perspective of commercial distribution business, the four enterprises have achieved positive growth, and the rankings of Sinopharm Holdings, Shanghai Pharmaceutical and China Resources Pharmaceutical remain unchanged from the previous year, and they are still the "iron triangle"
in China.
in China.
In the first half of 2022, Jointown Pharmaceutical's distribution and supply chain business grew steadily, achieving sales revenue of 59.
197 billion yuan, an increase of 9.
75% year-on-year, making it the fastest growing enterprise among the four companies, with a gross profit of 3.
983 billion yuan
.
197 billion yuan, an increase of 9.
75% year-on-year, making it the fastest growing enterprise among the four companies, with a gross profit of 3.
983 billion yuan
.
It is reported that pharmaceutical distribution is the core business of the six main businesses of Jointown, and the sales growth in the first half of the year comes from the company's continuous strengthening of strategic cooperation between county-level business and top 100 chains during the reporting period, expanding chain entrusted distribution projects, iteratively upgrading digital empowerment tools such as Jointown B2B network and "Smart Medicine", and improving the service capabilities
of the pharmaceutical supply chain.
of the pharmaceutical supply chain.
Sinopharm Holdings: The distribution business achieved sales of 196.
524 billion yuan, an increase of 3.
19%
year-on-year.
524 billion yuan, an increase of 3.
19%
year-on-year.
Shanghai Pharmaceutical: The distribution business achieved sales of 99.
157 billion yuan, an increase of 7.
21%
year-on-year.
157 billion yuan, an increase of 7.
21%
year-on-year.
CR Pharmaceutical: Distribution business achieved sales of HK$104.
396 billion, an increase of 8.
4%
year-on-year.
396 billion, an increase of 8.
4%
year-on-year.
Jointown: The distribution business achieved sales of 59.
197 billion yuan, an increase of 9.
75%
year-on-year.
197 billion yuan, an increase of 9.
75%
year-on-year.
In the retail business, Shanghai Pharmaceutical co-ordinated the negative growth, sinopharm holdings continued to increase the proportion of dual-channel pharmacies, hospital-side stores, and medical insurance co-ordination pharmacies
Under the influence of a series of medical reform policies such as "dual channel" and prescription outflow, the four actively explore the transformation of business formats and continue to promote the rapid growth of
the retail sector.
Its retail business revenue of China Pharmaceutical Holdings still stands out
.
the retail sector.
Its retail business revenue of China Pharmaceutical Holdings still stands out
.
During the reporting period, sinopharm's pharmaceutical retail business revenue totaled 15.
274 billion yuan, an increase of 11.
31% year-on-year, of which retail business revenue accounted for 5.
65%, an increase of 0.
31 percentage points year-on-year, about twice
the sum of the other three retail revenues.
274 billion yuan, an increase of 11.
31% year-on-year, of which retail business revenue accounted for 5.
65%, an increase of 0.
31 percentage points year-on-year, about twice
the sum of the other three retail revenues.
In the first half of 2022, Sinopharm Holdings continued to strengthen the qualification acquisition of "dual-channel pharmacies" and "medical insurance designated pharmacies", and increased the proportion
of dual-channel pharmacies, hospital-side stores, medical insurance co-ordination pharmacies and other formats with obvious service advantages.
of dual-channel pharmacies, hospital-side stores, medical insurance co-ordination pharmacies and other formats with obvious service advantages.
By the end of June 2022, the total number of Sinopharm Retail Stores reached 10,569, an increase of 310 from the end of 2021
.
Among them, there are 9137 NUS pharmacies, an increase of 339 from the end of 2021; There are 1432 specialty pharmacies, 29 fewer than at the end of 2021
.
The number of dual-channel stores totaled 676, an increase of 273 compared with the end of 2021, and the number of stores and same-store sales grew rapidly, providing a strong guarantee
for the Group's retail business to achieve stable growth in the first half of the severe epidemic.
.
Among them, there are 9137 NUS pharmacies, an increase of 339 from the end of 2021; There are 1432 specialty pharmacies, 29 fewer than at the end of 2021
.
The number of dual-channel stores totaled 676, an increase of 273 compared with the end of 2021, and the number of stores and same-store sales grew rapidly, providing a strong guarantee
for the Group's retail business to achieve stable growth in the first half of the severe epidemic.
In addition, Sinopharm took the lead in building a "Sinopharm Station" distribution network that combines online and offline with the formation of "Internet Hospital Consultation + Logistics Trunk Line Transportation + Retail Pharmacy Last Kilometer Distribution" in Shanghai, according to the announcement, in about 2 months in Shanghai, it has successfully docked more than 40 Internet hospitals and 8 administrative districts, undertaken more than 300,000 Internet hospital orders, and continuously enhanced
its online and offline collaboration capabilities.
its online and offline collaboration capabilities.
In the first half of 2022, CR Pharma's pharmaceutical retail business recorded revenue of HK$4.
061 billion, an increase of 13.
0% year-on-year, mainly due to the rapid growth of high-value direct drug delivery (DTP) business revenue, with a revenue of approximately RMB2.
42 billion during the reporting period, an increase of about 15%
year-on-year.
061 billion, an increase of 13.
0% year-on-year, mainly due to the rapid growth of high-value direct drug delivery (DTP) business revenue, with a revenue of approximately RMB2.
42 billion during the reporting period, an increase of about 15%
year-on-year.
Retail gross margin was 8.
4%, down 0.
6 percentage points from the year-ago quarter, primarily due to an increase in
revenue from the DTP business with lower gross margin.
As of June 30, 2022, Cr Resources had a total of 787 self-operated retail pharmacies, of which the total number of DTP specialty pharmacies had reached 221 (of which?).
Dual channel? 110 pharmacies).
4%, down 0.
6 percentage points from the year-ago quarter, primarily due to an increase in
revenue from the DTP business with lower gross margin.
As of June 30, 2022, Cr Resources had a total of 787 self-operated retail pharmacies, of which the total number of DTP specialty pharmacies had reached 221 (of which?).
Dual channel? 110 pharmacies).
According to the annual report, Shanghai Pharmaceutical's pharmaceutical retail business achieved sales revenue of 3.
531 billion yuan during the reporting period, down 4.
80% year-on-year, and the gross profit margin was 12.
17%, making it the only negative growth enterprise
.
Shanghai Pharmaceutical's domestic online and offline integrated pharmaceutical retail business covers more than 2,000 brand retail chain pharmacies in 16 provinces, autonomous regions and municipalities across the country, providing customers with efficient, professional and safe services
.
531 billion yuan during the reporting period, down 4.
80% year-on-year, and the gross profit margin was 12.
17%, making it the only negative growth enterprise
.
Shanghai Pharmaceutical's domestic online and offline integrated pharmaceutical retail business covers more than 2,000 brand retail chain pharmacies in 16 provinces, autonomous regions and municipalities across the country, providing customers with efficient, professional and safe services
.
During the reporting period, Jointown's pharmaceutical retail business achieved sales of 1.
048 billion yuan, an increase of 14.
11% year-on-year, and the scale of revenue continued to expand, becoming the four fastest growing enterprises
.
Achieved gross profit of 186 million yuan and gross profit margin of 17.
72%.
048 billion yuan, an increase of 14.
11% year-on-year, and the scale of revenue continued to expand, becoming the four fastest growing enterprises
.
Achieved gross profit of 186 million yuan and gross profit margin of 17.
72%.
During the reporting period, the total number of good pharmacist retail pharmacies reached 8516 at the end of the period, and more than 4700 store systems were launched; In terms of professional pharmacies, the company has 3 DTP/"dual-channel" pharmacies and 2 door-heavy and slow pharmacies, and many pharmacies around the world are actively applying for the qualification
of "dual-channel" and door-heavy and slow pharmacies.
of "dual-channel" and door-heavy and slow pharmacies.
The revenue of medical device business increased steadily, Sinopharm Holdings achieved an operating income of 53.
684 billion yuan, and the non-pharmaceutical business of Shanghai medical devices and big health increased by about 55% year-on-year.
684 billion yuan, and the non-pharmaceutical business of Shanghai medical devices and big health increased by about 55% year-on-year.
In 2022, the national organization and alliance procurement of high-value medical consumables have formed a normalized pattern, and the entire device distribution industry has also transformed towards scale and intensification, and the medical device business has become one
of the key strategic sectors of the four enterprises to focus on the layout.
of the key strategic sectors of the four enterprises to focus on the layout.
According to the data released by the four companies, in the medical device business in the first half of 2022, Sinopharm Holdings achieved an operating income of 53.
684 billion yuan, accounting for 19.
86% of the group's total revenue, an increase of 12.
36% year-on-year, far exceeding the sum of the revenues of the three enterprises
.
The increase was primarily due to the expansion
of the Group's medical device business.
Operating profit margin increased by 0.
64 percentage points year-on-year, laying a solid foundation
for the device sector to achieve steady annual growth.
684 billion yuan, accounting for 19.
86% of the group's total revenue, an increase of 12.
36% year-on-year, far exceeding the sum of the revenues of the three enterprises
.
The increase was primarily due to the expansion
of the Group's medical device business.
Operating profit margin increased by 0.
64 percentage points year-on-year, laying a solid foundation
for the device sector to achieve steady annual growth.
During the reporting period, Shanghai Pharmaceutical sold about 16.
7 billion yuan in non-pharmaceutical businesses such as equipment and big health, an increase of about 55% year-on-year, ranking first
among the four companies.
Among them, Shanghai Pharmaceutical Holdings actively expanded cooperation with head suppliers in the fields of intracardiac intervention, peripheral intervention, cryoablation, and large-scale release equipment, and carried out a total of 363 equipment recruitment projects in the first half of the year, with a total winning bid amount of 1.
2 billion
.
In the first half of the year, Shanghai Pharmaceutical Science Park introduced more than 8,000 new device products
.
7 billion yuan in non-pharmaceutical businesses such as equipment and big health, an increase of about 55% year-on-year, ranking first
among the four companies.
Among them, Shanghai Pharmaceutical Holdings actively expanded cooperation with head suppliers in the fields of intracardiac intervention, peripheral intervention, cryoablation, and large-scale release equipment, and carried out a total of 363 equipment recruitment projects in the first half of the year, with a total winning bid amount of 1.
2 billion
.
In the first half of the year, Shanghai Pharmaceutical Science Park introduced more than 8,000 new device products
.
In addition, Shanghai Pharmaceutical actively deploys the whole country, successively establishing Shanghai Pharmaceutical (Hangzhou) Medical Device Co.
, Ltd.
and Shanghai Pharmaceutical (Sichuan) Medical Equipment Co.
, Ltd.
, and focusing on promoting the establishment
of Shandong and Beijing device platforms.
At the same time, we will actively explore the transformation of sales representatives, improve terminal access capabilities and clinical value-added service capabilities, prepare for the new normal of equipment collection, and help the sustainable development of
the business.
, Ltd.
and Shanghai Pharmaceutical (Sichuan) Medical Equipment Co.
, Ltd.
, and focusing on promoting the establishment
of Shandong and Beijing device platforms.
At the same time, we will actively explore the transformation of sales representatives, improve terminal access capabilities and clinical value-added service capabilities, prepare for the new normal of equipment collection, and help the sustainable development of
the business.
Cr Pharma's device distribution business expanded rapidly during the reporting period, achieving revenue of about RMB14.
3 billion, a significant increase of about 39% over the same period of the previous year, of which IVD diagnostic reagents, comprehensive consumables and orthopedic business revenue achieved rapid growth
.
3 billion, a significant increase of about 39% over the same period of the previous year, of which IVD diagnostic reagents, comprehensive consumables and orthopedic business revenue achieved rapid growth
.
During the reporting period, Jointown achieved a comprehensive breakthrough in the product lines of the six core tracks of major surgery and intervention, orthopedics, medical equipment, IVD, household instruments and nursing consumables, fully promoted its own brand, built a professional supply chain service system and after-sales service system, and achieved sales revenue of 14 billion yuan in the medical device sector, an increase of 18.
06% year-on-year, accounting for 20.
60% of the company's overall sales; Gross profit was RMB1.
014 billion, up 10.
61% year-on-year
06% year-on-year, accounting for 20.
60% of the company's overall sales; Gross profit was RMB1.
014 billion, up 10.
61% year-on-year
Under the multiple influences of policies and markets, the profits of China's medical device circulation link have been greatly compressed, and enterprises have explored diversified development, actively explored innovation, transformation and upgrading, and focused on the development of
innovative service models such as SPD.
Four circulation giants bore the brunt of the outbreak and occupied the main operating markets
of SPD.
innovative service models such as SPD.
Four circulation giants bore the brunt of the outbreak and occupied the main operating markets
of SPD.
Sinopharm Holdings: As of the end of the reporting period, there were more than 1,500 centralized distribution and SPD projects underway, and more than 150 new SPD projects and consolidation projects were added in the first half of this year alone
.
.
CR Pharmaceutical: During the reporting period, 23 new SPD projects were added, and a regional comprehensive inspection center project was newly landed, and there are currently more than 100 SPD and centralized distribution projects
.
.
Jointown: SpD business takes digital transformation as the starting point and continues to upgrade services, with 18 newly signed hospitals and more than
100 hospital customers during the reporting period.
100 hospital customers during the reporting period.
R&D investment of China Resources Pharmaceutical and Jointown increased by more than 30% year-on-year
In the first half of 2022, CR Pharma's total R&D expenditure was approximately HK$1,005 million, an increase of 34.
5%
year-on-year.
As of June 30, 2022, CR New Product Development has nearly 300 research projects, including nearly 100 new drug projects, mainly involving oncology and immunity, metabolism and endocrinology, respiratory system, blood, cardiovascular, and classic recipes of traditional Chinese medicine
.
5%
year-on-year.
As of June 30, 2022, CR New Product Development has nearly 300 research projects, including nearly 100 new drug projects, mainly involving oncology and immunity, metabolism and endocrinology, respiratory system, blood, cardiovascular, and classic recipes of traditional Chinese medicine
.
By the end of the reporting period, 64 consistency evaluation projects had been focused, and more than 30 projects had carried out bioequivalence clinical trials
.
During the reporting period, a total of eight products, including metronidazole tablets, lincomycin hydrochloride injection, ambroxol hydrochloride injection, clindamycin phosphate injection, allopurinol tablets, gliquantel tablets, metronidazole sodium chloride injection (100ml), and cefotaxime sodium for injection passed the consistency evaluation, of which gliquinone tablets were the first of the same variety to be evaluated
.
.
During the reporting period, a total of eight products, including metronidazole tablets, lincomycin hydrochloride injection, ambroxol hydrochloride injection, clindamycin phosphate injection, allopurinol tablets, gliquantel tablets, metronidazole sodium chloride injection (100ml), and cefotaxime sodium for injection passed the consistency evaluation, of which gliquinone tablets were the first of the same variety to be evaluated
.
Shanghai Pharmaceutical is also increasing its R&D investment, with a total R&D investment of 968 million yuan in the first half of 2022, accounting for 7.
41%
of industrial sales revenue.
Among them, the research and development expenses were 810 million yuan, down 7.
99% year-on-year, accounting for 6.
20%
of the industrial sales revenue.
Up to now, the company's clinical applications have been accepted and entered the clinical research stage of 50 new drug pipelines, including 42 innovative drugs and 8 improved new drugs
.
Six of the innovative drug pipelines are already in critical studies or clinical phase III
.
41%
of industrial sales revenue.
Among them, the research and development expenses were 810 million yuan, down 7.
99% year-on-year, accounting for 6.
20%
of the industrial sales revenue.
Up to now, the company's clinical applications have been accepted and entered the clinical research stage of 50 new drug pipelines, including 42 innovative drugs and 8 improved new drugs
.
Six of the innovative drug pipelines are already in critical studies or clinical phase III
.
In terms of generic drugs, so far in 2022, 10 varieties (11 specifications) of the consistency evaluation approval (according to the approval time) have been newly obtained, so that the cumulative number of approved products with consistency evaluation has increased to 45 varieties (67 specifications).
Jointown's R&D expenditure in the first half of 2022 reached 83 million yuan, an increase of 32.
27%
year-on-year.
For the substantial increase in R&D expenses, Jointown said in its semi-annual report that it was mainly due to
the increase in R&D of projects such as cell engineering, medicinal material planting and processing and standardization construction, and drug research and development expenditure.
27%
year-on-year.
For the substantial increase in R&D expenses, Jointown said in its semi-annual report that it was mainly due to
the increase in R&D of projects such as cell engineering, medicinal material planting and processing and standardization construction, and drug research and development expenditure.
Through the performance of commercial companies in the first half of the year, we can see the fundamentals of the industry: the growth rate of industrial and circulation performance has slowed down, and some areas have even experienced negative growth
.
I hope that the industry boom in the second half of the year can be fully boosted!
.
I hope that the industry boom in the second half of the year can be fully boosted!
Recently, the four major listed enterprises in the domestic pharmaceutical business: Sinopharm Holdings, Shanghai Pharmaceutical, China Resources Pharmaceutical and Jointown have successively released their annual reports
for the first half of 2022.
Medicinefor the first half of 2022.
Overall, the revenue growth rate of the four companies has changed from the double-digit growth of revenue in the same period last year, all of which are single digits, and the growth rate is not much
different from each other.
However, Sinopharm Holdings still maintains its industry leadership, with revenue of 261.
471 billion yuan in the first half of 2022, and its revenue is almost the sum of the revenues of Shanghai Pharmaceutical, China Resources and
Jointown.
different from each other.
However, Sinopharm Holdings still maintains its industry leadership, with revenue of 261.
471 billion yuan in the first half of 2022, and its revenue is almost the sum of the revenues of Shanghai Pharmaceutical, China Resources and
Jointown.
In terms of net profit, China Resources Pharmaceutical performed prominently, with net profit in the first half of 2022 increasing by 26.
2% year-on-year to HK$5.
17 billion, and net profit attributable to the mother significantly increasing by 24.
1% year-on-year to HK$3.
03 billion, becoming the first enterprise in the four companies in terms
of revenue and net profit growth.
2% year-on-year to HK$5.
17 billion, and net profit attributable to the mother significantly increasing by 24.
1% year-on-year to HK$3.
03 billion, becoming the first enterprise in the four companies in terms
of revenue and net profit growth.
The net profit of Jointown continued its negative growth, and the net profit attributable to the mother decreased by 41.
58%
year-on-year.
For the negative growth of profit, Jointown said in the report that the fair value change caused by the change in the fair value of the company's shares held by the company in the same period last year was 1.
193 billion yuan, while the non-recurring profit and loss in the reporting period was only 163 million yuan
.
58%
year-on-year.
For the negative growth of profit, Jointown said in the report that the fair value change caused by the change in the fair value of the company's shares held by the company in the same period last year was 1.
193 billion yuan, while the non-recurring profit and loss in the reporting period was only 163 million yuan
.
For the impact of collection and mining, Jointown said that the benefits outweigh the disadvantages: according to the statistics of 2021, the variety affected by the collection and mining of the company accounts for about 3% of the total business, and this part of the business will have a certain impact due to price reduction, but due to the relatively small proportion, the impact is not large; However, in the long run, the policy will bring rare development opportunities
for the company to expand the pure sales business of the hospital and the out-of-hospital market and the general generation brand promotion business.
for the company to expand the pure sales business of the hospital and the out-of-hospital market and the general generation brand promotion business.
Sinopharm Holdings: Revenue in the first half of 2022 was 261.
471 billion yuan, an increase of 4.
96% year-on-year; Attributable net profit reached RMB3.
694 billion, up 3.
1%
year-on-year.
471 billion yuan, an increase of 4.
96% year-on-year; Attributable net profit reached RMB3.
694 billion, up 3.
1%
year-on-year.
Shanghai Pharmaceutical: Revenue in the first half of 2022 was 111.
707 billion yuan, an increase of 6.
15% year-on-year; Attributable net profit reached 3.
696 billion yuan, an increase of 3.
58%
year-on-year.
707 billion yuan, an increase of 6.
15% year-on-year; Attributable net profit reached 3.
696 billion yuan, an increase of 3.
58%
year-on-year.
CR Pharmaceutical: Revenue in the first half of 2022 was HK$125.
716 billion, an increase of 9.
8% year-on-year; Attributable net profit reached HK$3,025 million, up 24.
1%
year-on-year.
716 billion, an increase of 9.
8% year-on-year; Attributable net profit reached HK$3,025 million, up 24.
1%
year-on-year.
Jointown: Revenue in the first half of 2022 was 67.
984 billion yuan, an increase of 9.
69% year-on-year; Net profit attributable to the mother reached 169 million yuan, down 41.
58%
year-on-year.
984 billion yuan, an increase of 9.
69% year-on-year; Net profit attributable to the mother reached 169 million yuan, down 41.
58%
year-on-year.
In the distribution sector, the four enterprises all showed positive growth, with Jointown showing the largest increase, and the distribution business achieved sales of 59.
197 billion yuan, an increase of 9.
75%
year-on-year.
197 billion yuan, an increase of 9.
75%
year-on-year.
From the perspective of commercial distribution business, the four enterprises have achieved positive growth, and the rankings of Sinopharm Holdings, Shanghai Pharmaceutical and China Resources Pharmaceutical remain unchanged from the previous year, and they are still the "iron triangle"
in China.
in China.
In the first half of 2022, Jointown Pharmaceutical's distribution and supply chain business grew steadily, achieving sales revenue of 59.
197 billion yuan, an increase of 9.
75% year-on-year, making it the fastest growing enterprise among the four companies, with a gross profit of 3.
983 billion yuan
.
197 billion yuan, an increase of 9.
75% year-on-year, making it the fastest growing enterprise among the four companies, with a gross profit of 3.
983 billion yuan
.
It is reported that pharmaceutical distribution is the core business of the six main businesses of Jointown, and the sales growth in the first half of the year comes from the company's continuous strengthening of strategic cooperation between county-level business and top 100 chains during the reporting period, expanding chain entrusted distribution projects, iteratively upgrading digital empowerment tools such as Jointown B2B network and "Smart Medicine", and improving the service capabilities
of the pharmaceutical supply chain.
of the pharmaceutical supply chain.
Sinopharm Holdings: The distribution business achieved sales of 196.
524 billion yuan, an increase of 3.
19%
year-on-year.
524 billion yuan, an increase of 3.
19%
year-on-year.
Shanghai Pharmaceutical: The distribution business achieved sales of 99.
157 billion yuan, an increase of 7.
21%
year-on-year.
157 billion yuan, an increase of 7.
21%
year-on-year.
CR Pharmaceutical: Distribution business achieved sales of HK$104.
396 billion, an increase of 8.
4%
year-on-year.
396 billion, an increase of 8.
4%
year-on-year.
Jointown: The distribution business achieved sales of 59.
197 billion yuan, an increase of 9.
75%
year-on-year.
197 billion yuan, an increase of 9.
75%
year-on-year.
In the retail business, Shanghai Pharmaceutical co-ordinated the negative growth, sinopharm holdings continued to increase the proportion of dual-channel pharmacies, hospital-side stores, and medical insurance co-ordination pharmacies
Under the influence of a series of medical reform policies such as "dual channel" and prescription outflow, the four actively explore the transformation of business formats and continue to promote the rapid growth of
the retail sector.
Its retail business revenue of China Pharmaceutical Holdings still stands out
.
the retail sector.
Its retail business revenue of China Pharmaceutical Holdings still stands out
.
During the reporting period, sinopharm's pharmaceutical retail business revenue totaled 15.
274 billion yuan, an increase of 11.
31% year-on-year, of which retail business revenue accounted for 5.
65%, an increase of 0.
31 percentage points year-on-year, about twice
the sum of the other three retail revenues.
274 billion yuan, an increase of 11.
31% year-on-year, of which retail business revenue accounted for 5.
65%, an increase of 0.
31 percentage points year-on-year, about twice
the sum of the other three retail revenues.
In the first half of 2022, Sinopharm Holdings continued to strengthen the qualification acquisition of "dual-channel pharmacies" and "medical insurance designated pharmacies", and increased the proportion
of dual-channel pharmacies, hospital-side stores, medical insurance co-ordination pharmacies and other formats with obvious service advantages.
of dual-channel pharmacies, hospital-side stores, medical insurance co-ordination pharmacies and other formats with obvious service advantages.
By the end of June 2022, the total number of Sinopharm Retail Stores reached 10,569, an increase of 310 from the end of 2021
.
Among them, there are 9137 NUS pharmacies, an increase of 339 from the end of 2021; There are 1432 specialty pharmacies, 29 fewer than at the end of 2021
.
The number of dual-channel stores totaled 676, an increase of 273 compared with the end of 2021, and the number of stores and same-store sales grew rapidly, providing a strong guarantee
for the Group's retail business to achieve stable growth in the first half of the severe epidemic.
.
Among them, there are 9137 NUS pharmacies, an increase of 339 from the end of 2021; There are 1432 specialty pharmacies, 29 fewer than at the end of 2021
.
The number of dual-channel stores totaled 676, an increase of 273 compared with the end of 2021, and the number of stores and same-store sales grew rapidly, providing a strong guarantee
for the Group's retail business to achieve stable growth in the first half of the severe epidemic.
In addition, Sinopharm took the lead in building a "Sinopharm Station" distribution network that combines online and offline with the formation of "Internet Hospital Consultation + Logistics Trunk Line Transportation + Retail Pharmacy Last Kilometer Distribution" in Shanghai, according to the announcement, in about 2 months in Shanghai, it has successfully docked more than 40 Internet hospitals and 8 administrative districts, undertaken more than 300,000 Internet hospital orders, and continuously enhanced
its online and offline collaboration capabilities.
its online and offline collaboration capabilities.
In the first half of 2022, CR Pharma's pharmaceutical retail business recorded revenue of HK$4.
061 billion, an increase of 13.
0% year-on-year, mainly due to the rapid growth of high-value direct drug delivery (DTP) business revenue, with a revenue of approximately RMB2.
42 billion during the reporting period, an increase of about 15%
year-on-year.
061 billion, an increase of 13.
0% year-on-year, mainly due to the rapid growth of high-value direct drug delivery (DTP) business revenue, with a revenue of approximately RMB2.
42 billion during the reporting period, an increase of about 15%
year-on-year.
Retail gross margin was 8.
4%, down 0.
6 percentage points from the year-ago quarter, primarily due to an increase in
revenue from the DTP business with lower gross margin.
As of June 30, 2022, Cr Resources had a total of 787 self-operated retail pharmacies, of which the total number of DTP specialty pharmacies had reached 221 (of which?).
Dual channel? 110 pharmacies).
4%, down 0.
6 percentage points from the year-ago quarter, primarily due to an increase in
revenue from the DTP business with lower gross margin.
As of June 30, 2022, Cr Resources had a total of 787 self-operated retail pharmacies, of which the total number of DTP specialty pharmacies had reached 221 (of which?).
Dual channel? 110 pharmacies).
According to the annual report, Shanghai Pharmaceutical's pharmaceutical retail business achieved sales revenue of 3.
531 billion yuan during the reporting period, down 4.
80% year-on-year, and the gross profit margin was 12.
17%, making it the only negative growth enterprise
.
Shanghai Pharmaceutical's domestic online and offline integrated pharmaceutical retail business covers more than 2,000 brand retail chain pharmacies in 16 provinces, autonomous regions and municipalities across the country, providing customers with efficient, professional and safe services
.
531 billion yuan during the reporting period, down 4.
80% year-on-year, and the gross profit margin was 12.
17%, making it the only negative growth enterprise
.
Shanghai Pharmaceutical's domestic online and offline integrated pharmaceutical retail business covers more than 2,000 brand retail chain pharmacies in 16 provinces, autonomous regions and municipalities across the country, providing customers with efficient, professional and safe services
.
During the reporting period, Jointown's pharmaceutical retail business achieved sales of 1.
048 billion yuan, an increase of 14.
11% year-on-year, and the scale of revenue continued to expand, becoming the four fastest growing enterprises
.
Achieved gross profit of 186 million yuan and gross profit margin of 17.
72%.
048 billion yuan, an increase of 14.
11% year-on-year, and the scale of revenue continued to expand, becoming the four fastest growing enterprises
.
Achieved gross profit of 186 million yuan and gross profit margin of 17.
72%.
During the reporting period, the total number of good pharmacist retail pharmacies reached 8516 at the end of the period, and more than 4700 store systems were launched; In terms of professional pharmacies, the company has 3 DTP/"dual-channel" pharmacies and 2 door-heavy and slow pharmacies, and many pharmacies around the world are actively applying for the qualification
of "dual-channel" and door-heavy and slow pharmacies.
of "dual-channel" and door-heavy and slow pharmacies.
The revenue of medical device business increased steadily, Sinopharm Holdings achieved an operating income of 53.
684 billion yuan, and the non-pharmaceutical business of Shanghai medical devices and big health increased by about 55% year-on-year.
Medical devices Medical devices684 billion yuan, and the non-pharmaceutical business of Shanghai medical devices and big health increased by about 55% year-on-year.
In 2022, the national organization and alliance procurement of high-value medical consumables have formed a normalized pattern, and the entire device distribution industry has also transformed towards scale and intensification, and the medical device business has become one
of the key strategic sectors of the four enterprises to focus on the layout.
Enterprise enterpriseof the key strategic sectors of the four enterprises to focus on the layout.
According to the data released by the four companies, in the medical device business in the first half of 2022, Sinopharm Holdings achieved an operating income of 53.
684 billion yuan, accounting for 19.
86% of the group's total revenue, an increase of 12.
36% year-on-year, far exceeding the sum of the revenues of the three enterprises
.
The increase was primarily due to the expansion
of the Group's medical device business.
Operating profit margin increased by 0.
64 percentage points year-on-year, laying a solid foundation
for the device sector to achieve steady annual growth.
684 billion yuan, accounting for 19.
86% of the group's total revenue, an increase of 12.
36% year-on-year, far exceeding the sum of the revenues of the three enterprises
.
The increase was primarily due to the expansion
of the Group's medical device business.
Operating profit margin increased by 0.
64 percentage points year-on-year, laying a solid foundation
for the device sector to achieve steady annual growth.
During the reporting period, Shanghai Pharmaceutical sold about 16.
7 billion yuan in non-pharmaceutical businesses such as equipment and big health, an increase of about 55% year-on-year, ranking first
among the four companies.
Among them, Shanghai Pharmaceutical Holdings actively expanded cooperation with head suppliers in the fields of intracardiac intervention, peripheral intervention, cryoablation, and large-scale release equipment, and carried out a total of 363 equipment recruitment projects in the first half of the year, with a total winning bid amount of 1.
2 billion
.
In the first half of the year, Shanghai Pharmaceutical Science Park introduced more than 8,000 new device products
.
7 billion yuan in non-pharmaceutical businesses such as equipment and big health, an increase of about 55% year-on-year, ranking first
among the four companies.
Among them, Shanghai Pharmaceutical Holdings actively expanded cooperation with head suppliers in the fields of intracardiac intervention, peripheral intervention, cryoablation, and large-scale release equipment, and carried out a total of 363 equipment recruitment projects in the first half of the year, with a total winning bid amount of 1.
2 billion
.
In the first half of the year, Shanghai Pharmaceutical Science Park introduced more than 8,000 new device products
.
In addition, Shanghai Pharmaceutical actively deploys the whole country, successively establishing Shanghai Pharmaceutical (Hangzhou) Medical Device Co.
, Ltd.
and Shanghai Pharmaceutical (Sichuan) Medical Equipment Co.
, Ltd.
, and focusing on promoting the establishment
of Shandong and Beijing device platforms.
At the same time, we will actively explore the transformation of sales representatives, improve terminal access capabilities and clinical value-added service capabilities, prepare for the new normal of equipment collection, and help the sustainable development of
the business.
, Ltd.
and Shanghai Pharmaceutical (Sichuan) Medical Equipment Co.
, Ltd.
, and focusing on promoting the establishment
of Shandong and Beijing device platforms.
At the same time, we will actively explore the transformation of sales representatives, improve terminal access capabilities and clinical value-added service capabilities, prepare for the new normal of equipment collection, and help the sustainable development of
the business.
Cr Pharma's device distribution business expanded rapidly during the reporting period, achieving revenue of about RMB14.
3 billion, a significant increase of about 39% over the same period of the previous year, of which IVD diagnostic reagents, comprehensive consumables and orthopedic business revenue achieved rapid growth
.
3 billion, a significant increase of about 39% over the same period of the previous year, of which IVD diagnostic reagents, comprehensive consumables and orthopedic business revenue achieved rapid growth
.
During the reporting period, Jointown achieved a comprehensive breakthrough in the product lines of the six core tracks of major surgery and intervention, orthopedics, medical equipment, IVD, household instruments and nursing consumables, fully promoted its own brand, built a professional supply chain service system and after-sales service system, and achieved sales revenue of 14 billion yuan in the medical device sector, an increase of 18.
06% year-on-year, accounting for 20.
60% of the company's overall sales; Gross profit was RMB1.
014 billion, up 10.
61% year-on-year
06% year-on-year, accounting for 20.
60% of the company's overall sales; Gross profit was RMB1.
014 billion, up 10.
61% year-on-year
Under the multiple influences of policies and markets, the profits of China's medical device circulation link have been greatly compressed, and enterprises have explored diversified development, actively explored innovation, transformation and upgrading, and focused on the development of
innovative service models such as SPD.
Four circulation giants bore the brunt of the outbreak and occupied the main operating markets
of SPD.
innovative service models such as SPD.
Four circulation giants bore the brunt of the outbreak and occupied the main operating markets
of SPD.
Sinopharm Holdings: As of the end of the reporting period, there were more than 1,500 centralized distribution and SPD projects underway, and more than 150 new SPD projects and consolidation projects were added in the first half of this year alone
.
.
CR Pharmaceutical: During the reporting period, 23 new SPD projects were added, and a regional comprehensive inspection center project was newly landed, and there are currently more than 100 SPD and centralized distribution projects
.
.
Jointown: SpD business takes digital transformation as the starting point and continues to upgrade services, with 18 newly signed hospitals and more than
100 hospital customers during the reporting period.
Hospital Hospital100 hospital customers during the reporting period.
R&D investment of China Resources Pharmaceutical and Jointown increased by more than 30% year-on-year
R&D investment of China Resources Pharmaceutical and Jointown increased by more than 30% year-on-year In the first half of 2022, CR Pharma's total R&D expenditure was approximately HK$1,005 million, an increase of 34.
5%
year-on-year.
As of June 30, 2022, CR New Product Development has nearly 300 research projects, including nearly 100 new drug projects, mainly involving oncology and immunity, metabolism and endocrinology, respiratory system, blood, cardiovascular, and classic recipes of traditional Chinese medicine
.
5%
year-on-year.
As of June 30, 2022, CR New Product Development has nearly 300 research projects, including nearly 100 new drug projects, mainly involving oncology and immunity, metabolism and endocrinology, respiratory system, blood, cardiovascular, and classic recipes of traditional Chinese medicine
.
By the end of the reporting period, 64 consistency evaluation projects had been focused, and more than 30 projects had carried out bioequivalence clinical trials
.
During the reporting period, a total of eight products, including metronidazole tablets, lincomycin hydrochloride injection, ambroxol hydrochloride injection, clindamycin phosphate injection, allopurinol tablets, gliquantel tablets, metronidazole sodium chloride injection (100ml), and cefotaxime sodium for injection passed the consistency evaluation, of which gliquinone tablets were the first of the same variety to be evaluated
.
.
During the reporting period, a total of eight products, including metronidazole tablets, lincomycin hydrochloride injection, ambroxol hydrochloride injection, clindamycin phosphate injection, allopurinol tablets, gliquantel tablets, metronidazole sodium chloride injection (100ml), and cefotaxime sodium for injection passed the consistency evaluation, of which gliquinone tablets were the first of the same variety to be evaluated
.
Shanghai Pharmaceutical is also increasing its R&D investment, with a total R&D investment of 968 million yuan in the first half of 2022, accounting for 7.
41%
of industrial sales revenue.
Among them, the research and development expenses were 810 million yuan, down 7.
99% year-on-year, accounting for 6.
20%
of the industrial sales revenue.
Up to now, the company's clinical applications have been accepted and entered the clinical research stage of 50 new drug pipelines, including 42 innovative drugs and 8 improved new drugs
.
Six of the innovative drug pipelines are already in critical studies or clinical phase III
.
41%
of industrial sales revenue.
Among them, the research and development expenses were 810 million yuan, down 7.
99% year-on-year, accounting for 6.
20%
of the industrial sales revenue.
Up to now, the company's clinical applications have been accepted and entered the clinical research stage of 50 new drug pipelines, including 42 innovative drugs and 8 improved new drugs
.
Six of the innovative drug pipelines are already in critical studies or clinical phase III
.
In terms of generic drugs, so far in 2022, 10 varieties (11 specifications) of the consistency evaluation approval (according to the approval time) have been newly obtained, so that the cumulative number of approved products with consistency evaluation has increased to 45 varieties (67 specifications).
Jointown's R&D expenditure in the first half of 2022 reached 83 million yuan, an increase of 32.
27%
year-on-year.
For the substantial increase in R&D expenses, Jointown said in its semi-annual report that it was mainly due to
the increase in R&D of projects such as cell engineering, medicinal material planting and processing and standardization construction, and drug research and development expenditure.
Pharmaceuticals 27%
year-on-year.
For the substantial increase in R&D expenses, Jointown said in its semi-annual report that it was mainly due to
the increase in R&D of projects such as cell engineering, medicinal material planting and processing and standardization construction, and drug research and development expenditure.
